File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Imipenem/cilastatin as initial therapy for febrile neutropenic patients

TitleImipenem/cilastatin as initial therapy for febrile neutropenic patients
Authors
Issue Date1988
PublisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/
Citation
Journal Of Antimicrobial Chemotherapy, 1988, v. 22 n. 5, p. 765-770 How to Cite?
AbstractImipenem 2 g daily was administered intravenously to 40 evaluable patients with neutropenia and fever. Twenty-three patients had acute leukaemia and 17 malignant lymphoma. The overall response rate was 70.0%. Of the 14 patients with documented infection, 9 (64.3%) responded. Poorer responses were observed in patients with pneumonia (40%) or pseudomonal infection (50%). The response rate was significantly higher among patients with increasing neutrophil counts during therapy (P < 0.02). Fungal infection was a common cause of treatment failure. Gastrointestinal side effects and skin rashes were occasionally seen. No patients developed cental nervous system toxicity. Imipenem is a practical alternative to antibiotic combinations for management of neutropenic infection. However, careful monitoring is essential in the subgroups of patients with pneumonia or pseudomonal infections, who may require modifications of therapy.
Persistent Identifierhttp://hdl.handle.net/10722/161755
ISSN
2015 Impact Factor: 4.919
2015 SCImago Journal Rankings: 2.157
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_US
dc.contributor.authorYung, Ren_US
dc.contributor.authorChau, PYen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorLam, WKen_US
dc.contributor.authorSo, SYen_US
dc.contributor.authorTodd, Den_US
dc.date.accessioned2012-09-05T05:14:42Z-
dc.date.available2012-09-05T05:14:42Z-
dc.date.issued1988en_US
dc.identifier.citationJournal Of Antimicrobial Chemotherapy, 1988, v. 22 n. 5, p. 765-770en_US
dc.identifier.issn0305-7453en_US
dc.identifier.urihttp://hdl.handle.net/10722/161755-
dc.description.abstractImipenem 2 g daily was administered intravenously to 40 evaluable patients with neutropenia and fever. Twenty-three patients had acute leukaemia and 17 malignant lymphoma. The overall response rate was 70.0%. Of the 14 patients with documented infection, 9 (64.3%) responded. Poorer responses were observed in patients with pneumonia (40%) or pseudomonal infection (50%). The response rate was significantly higher among patients with increasing neutrophil counts during therapy (P < 0.02). Fungal infection was a common cause of treatment failure. Gastrointestinal side effects and skin rashes were occasionally seen. No patients developed cental nervous system toxicity. Imipenem is a practical alternative to antibiotic combinations for management of neutropenic infection. However, careful monitoring is essential in the subgroups of patients with pneumonia or pseudomonal infections, who may require modifications of therapy.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jac.oxfordjournals.org/en_US
dc.relation.ispartofJournal of Antimicrobial Chemotherapyen_US
dc.subject.meshAgranulocytosis - Complicationsen_US
dc.subject.meshCilastatin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshDipeptidases - Antagonists & Inhibitorsen_US
dc.subject.meshDrug Therapy, Combination - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFever Of Unknown Origin - Complications - Drug Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshImipenem - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMicrobial Sensitivity Testsen_US
dc.subject.meshNeutropenia - Complicationsen_US
dc.titleImipenem/cilastatin as initial therapy for febrile neutropenic patientsen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/jac/22.5.765-
dc.identifier.pmid3209533-
dc.identifier.scopuseid_2-s2.0-0023816592en_US
dc.identifier.volume22en_US
dc.identifier.issue5en_US
dc.identifier.spage765en_US
dc.identifier.epage770en_US
dc.identifier.isiWOS:A1988R092700025-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridYung, R=7005594277en_US
dc.identifier.scopusauthoridChau, PY=36509704300en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridSo, SY=7102397816en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats